Posted by Michael Wonder on 10 Jun 2021
Health Canada grants interim order authorisation for casirivimab and imdevimab for the treatment of mild to moderate COVID-19
10 June 2021 - Interim data shows treatment with casirivimab and imdevimab resulted in a statistically significant reduction in viral loads compared to placebo.
Roche Canada today announced that Health Canada has issued an interim order authorisation for casirivimab and imdevimab (REGN-COV2), to be administered together, for the treatment of mild to moderate coronavirus disease 2019 (COVID-19), confirmed by direct SARS-CoV-2 viral testing, in adults and adolescents (12 years of age and older weighing at least 40 kg) who are at high-risk for progressing to hospitalisation and/or death.
